ANI Pharmaceuticals Inc

BSFA

Company Profile

  • Business description

    ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

  • Contact

    210 Main Street West
    BaudetteMN56623
    USA

    T: +1 218 634-3500

    E: [email protected]

    https://www.anipharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    897

Stocks News & Analysis

stocks

Earnings up but shares overvalued for ASX gold miner

Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,351.904.90-0.05%
CAC 408,239.1813.550.16%
DAX 4024,308.7868.890.28%
Dow JONES (US)47,539.99332.870.71%
FTSE 1009,653.828.200.09%
HKSE26,433.70273.551.05%
NASDAQ23,650.31445.451.92%
Nikkei 22550,512.321,212.672.46%
NZX 50 Index13,391.5914.490.11%
S&P 5006,876.8385.141.25%
S&P/ASX 2009,055.602.20-0.02%
SSE Composite Index3,996.9446.631.18%

Market Movers